

Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Growth 2026-2032

<https://marketpublishers.com/r/G2A792748073EN.html>

Date: March 2026

Pages: 84

Price: US\$ 3,660.00 (Single User License)

ID: G2A792748073EN

Abstracts

The global Neurokinin Receptor Antagonists for Vasomotor Symptoms market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Neurokinin receptor antagonists for vasomotor symptoms are a class of medications designed to alleviate menopausal symptoms such as hot flashes and night sweats, which are primarily caused by hormonal fluctuations. By blocking these receptors, neurokinin receptor antagonists help reduce the frequency and intensity of vasomotor symptoms without the hormonal side effects associated with traditional hormone replacement therapies. An example of such a drug is fezolinetant, which has shown efficacy in clinical trials and has been approved for this indication. This therapeutic approach offers a promising non-hormonal alternative for managing menopausal symptoms, improving the quality of life for many women.

United States market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Neurokinin Receptor Antagonists for Vasomotor Symptoms players cover Astellas Pharma, Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the “Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Forecast” looks at past sales and reviews total world Neurokinin Receptor Antagonists for Vasomotor Symptoms sales in 2025, providing a comprehensive analysis by region and market sector of projected Neurokinin Receptor Antagonists for Vasomotor Symptoms sales for 2026 through 2032. With Neurokinin Receptor Antagonists for Vasomotor Symptoms sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Neurokinin Receptor Antagonists for Vasomotor Symptoms industry.

This Insight Report provides a comprehensive analysis of the global Neurokinin Receptor Antagonists for Vasomotor Symptoms landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurokinin Receptor Antagonists for Vasomotor Symptoms portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Neurokinin Receptor Antagonists for Vasomotor Symptoms market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurokinin Receptor Antagonists for Vasomotor Symptoms and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurokinin Receptor Antagonists for Vasomotor Symptoms.

This report presents a comprehensive overview, market shares, and growth opportunities of Neurokinin Receptor Antagonists for Vasomotor Symptoms market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Fezolinetant

Elinzanetant

Segmentation by Application:

Hospital and Clinic

Pharmacy

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Astellas Pharma

Bayer

Key Questions Addressed in this Report

What is the 10-year outlook for the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market?

What factors are driving Neurokinin Receptor Antagonists for Vasomotor Symptoms market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Neurokinin Receptor Antagonists for Vasomotor Symptoms market opportunities vary by end market size?
How does Neurokinin Receptor Antagonists for Vasomotor Symptoms break out by Type, by Application?

The report requires updating with new data and is sent in 48 hours after order is placed.

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Annual Sales 2021-2032

2.1.2 World Current & Future Analysis for Neurokinin Receptor Antagonists for Vasomotor Symptoms by Geographic Region, 2021, 2025 & 2032

2.1.3 World Current & Future Analysis for Neurokinin Receptor Antagonists for Vasomotor Symptoms by Country/Region, 2021, 2025 & 2032

2.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Type

2.2.1 Fezolinetant

2.2.2 Elinzanetant

2.2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type

2.2.3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2026)

2.2.3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue and Market Share by Type (2021-2026)

2.2.3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sale Price by Type (2021-2026)

2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Application

2.3.1 Hospital and Clinic

2.3.2 Pharmacy

2.3.3 Other

2.3.4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application

2.3.4.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sale Market Share by Application (2021-2026)

2.3.4.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Breakdown Data by Company

3.1.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Annual Sales by Company (2021-2026)

3.1.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Company (2021-2026)

3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Annual Revenue by Company (2021-2026)

3.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Company (2021-2026)

3.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Company (2021-2026)

3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sale Price by Company

3.4 Key Manufacturers Neurokinin Receptor Antagonists for Vasomotor Symptoms Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Location Distribution

3.4.2 Players Neurokinin Receptor Antagonists for Vasomotor Symptoms Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR NEUROKININ RECEPTOR ANTAGONISTS FOR VASOMOTOR SYMPTOMS BY GEOGRAPHIC REGION

4.1 World Historic Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Geographic Region (2021-2026)

4.1.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Annual Sales

by Geographic Region (2021-2026)

4.1.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country/Region (2021-2026)

4.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Annual Sales by Country/Region (2021-2026)

4.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Annual Revenue by Country/Region (2021-2026)

4.3 Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth

4.4 APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth

4.5 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth

4.6 Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth

5 AMERICAS

5.1 Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country

5.1.1 Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026)

5.1.2 Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2026)

5.2 Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026)

5.3 Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region

6.1.1 APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2021-2026)

6.1.2 APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2021-2026)

6.2 APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026)

6.3 APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms by Country

7.1.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026)

7.1.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2026)

7.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026)

7.3 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms by Country

8.1.1 Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026)

8.1.2 Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2026)

8.2 Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026)

8.3 Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Neurokinin Receptor Antagonists for Vasomotor Symptoms

10.3 Manufacturing Process Analysis of Neurokinin Receptor Antagonists for Vasomotor Symptoms

10.4 Industry Chain Structure of Neurokinin Receptor Antagonists for Vasomotor Symptoms

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors

11.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Customer

12 WORLD FORECAST REVIEW FOR NEUROKININ RECEPTOR ANTAGONISTS FOR VASOMOTOR SYMPTOMS BY GEOGRAPHIC REGION

12.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Forecast by Region

12.1.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Forecast by Region (2027-2032)

- 12.1.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Forecast by Type (2027-2032)
- 12.7 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Astellas Pharma

- 13.1.1 Astellas Pharma Company Information
- 13.1.2 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolios and Specifications
- 13.1.3 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.1.4 Astellas Pharma Main Business Overview
- 13.1.5 Astellas Pharma Latest Developments

13.2 Bayer

- 13.2.1 Bayer Company Information
- 13.2.2 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolios and Specifications
- 13.2.3 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.2.4 Bayer Main Business Overview
- 13.2.5 Bayer Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Neurokinin Receptor Antagonists for Vasomotor Symptoms Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Neurokinin Receptor Antagonists for Vasomotor Symptoms Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Fezolinetant

Table 4. Major Players of Elinzanetant

Table 5. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units)

Table 6. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2026)

Table 7. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2026) & (\$ million)

Table 8. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2021-2026)

Table 9. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sale Price by Type (2021-2026) & (US\$/Unit)

Table 10. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sale by Application (2021-2026) & (K Units)

Table 11. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sale Market Share by Application (2021-2026)

Table 12. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2026) & (\$ million)

Table 13. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2021-2026)

Table 14. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sale Price by Application (2021-2026) & (US\$/Unit)

Table 15. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Company (2021-2026) & (K Units)

Table 16. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Company (2021-2026)

Table 17. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Company (2021-2026) & (\$ millions)

Table 18. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Company (2021-2026)

Table 19. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sale Price

by Company (2021-2026) & (US\$/Unit)

Table 20. Key Manufacturers Neurokinin Receptor Antagonists for Vasomotor Symptoms Producing Area Distribution and Sales Area

Table 21. Players Neurokinin Receptor Antagonists for Vasomotor Symptoms Products Offered

Table 22. Neurokinin Receptor Antagonists for Vasomotor Symptoms Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Geographic Region (2021-2026) & (K Units)

Table 26. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share Geographic Region (2021-2026)

Table 27. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 28. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Geographic Region (2021-2026)

Table 29. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country/Region (2021-2026) & (K Units)

Table 30. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country/Region (2021-2026)

Table 31. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country/Region (2021-2026) & (\$ millions)

Table 32. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Country/Region (2021-2026)

Table 33. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units)

Table 34. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2026)

Table 35. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2026) & (\$ millions)

Table 36. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units)

Table 37. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units)

Table 38. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2021-2026) & (K Units)

Table 39. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Region (2021-2026)

Table 40. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2021-2026) & (\$ millions)

Table 41. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units)

Table 42. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units)

Table 43. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units)

Table 44. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2026) & (\$ millions)

Table 45. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units)

Table 46. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units)

Table 47. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units)

Table 48. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Country (2021-2026)

Table 49. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units)

Table 50. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units)

Table 51. Key Market Drivers & Growth Opportunities of Neurokinin Receptor Antagonists for Vasomotor Symptoms

Table 52. Key Market Challenges & Risks of Neurokinin Receptor Antagonists for Vasomotor Symptoms

Table 53. Key Industry Trends of Neurokinin Receptor Antagonists for Vasomotor Symptoms

Table 54. Neurokinin Receptor Antagonists for Vasomotor Symptoms Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors List

Table 57. Neurokinin Receptor Antagonists for Vasomotor Symptoms Customer List

Table 58. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Region (2027-2032) & (K Units)

Table 59. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 60. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032) & (K Units)

Table 61. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Annual

Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 62. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Region (2027-2032) & (K Units)

Table 63. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 64. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032) & (K Units)

Table 65. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 66. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Type (2027-2032) & (K Units)

Table 69. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 70. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Application (2027-2032) & (K Units)

Table 71. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 72. Astellas Pharma Basic Information, Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturing Base, Sales Area and Its Competitors

Table 73. Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolios and Specifications

Table 74. Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 75. Astellas Pharma Main Business

Table 76. Astellas Pharma Latest Developments

Table 77. Bayer Basic Information, Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturing Base, Sales Area and Its Competitors

Table 78. Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolios and Specifications

Table 79. Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 80. Bayer Main Business

Table 81. Bayer Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Neurokinin Receptor Antagonists for Vasomotor Symptoms

Figure 2. Neurokinin Receptor Antagonists for Vasomotor Symptoms Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate 2021-2032 (K Units)

Figure 7. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate 2021-2032 (\$ millions)

Figure 8. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 9. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country/Region (2025)

Figure 10. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 11. Product Picture of Fezolinetant

Figure 12. Product Picture of Elinzanetant

Figure 13. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type in 2026

Figure 14. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2021-2026)

Figure 15. Neurokinin Receptor Antagonists for Vasomotor Symptoms Consumed in Hospital and Clinic

Figure 16. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market: Hospital and Clinic (2021-2026) & (K Units)

Figure 17. Neurokinin Receptor Antagonists for Vasomotor Symptoms Consumed in Pharmacy

Figure 18. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market: Pharmacy (2021-2026) & (K Units)

Figure 19. Neurokinin Receptor Antagonists for Vasomotor Symptoms Consumed in Other

Figure 20. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market: Other (2021-2026) & (K Units)

Figure 21. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sale

Market Share by Application (2025)

Figure 22. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue

Market Share by Application in 2026

Figure 23. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by

Company in 2026 (K Units)

Figure 24. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales

Market Share by Company in 2026

Figure 25. Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by

Company in 2026 (\$ millions)

Figure 26. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue

Market Share by Company in 2026

Figure 27. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales

Market Share by Geographic Region (2021-2026)

Figure 28. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue

Market Share by Geographic Region in 2026

Figure 29. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales

2021-2026 (K Units)

Figure 30. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms

Revenue 2021-2026 (\$ millions)

Figure 31. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales

2021-2026 (K Units)

Figure 32. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue

2021-2026 (\$ millions)

Figure 33. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales

2021-2026 (K Units)

Figure 34. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue

2021-2026 (\$ millions)

Figure 35. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor

Symptoms Sales 2021-2026 (K Units)

Figure 36. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor

Symptoms Revenue 2021-2026 (\$ millions)

Figure 37. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales

Market Share by Country in 2026

Figure 38. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms

Revenue Market Share by Country (2021-2026)

Figure 39. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales

Market Share by Type (2021-2026)

Figure 40. Americas Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales

Market Share by Application (2021-2026)

Figure 41. United States Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 42. Canada Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 43. Mexico Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 44. Brazil Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 45. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Region in 2026

Figure 46. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region (2021-2026)

Figure 47. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2026)

Figure 48. APAC Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2021-2026)

Figure 49. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 50. Japan Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 51. South Korea Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 52. Southeast Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 53. India Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 54. Australia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 55. China Taiwan Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 56. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country in 2026

Figure 57. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Country (2021-2026)

Figure 58. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2026)

Figure 59. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2021-2026)

Figure 60. Germany Neurokinin Receptor Antagonists for Vasomotor Symptoms

Revenue Growth 2021-2026 (\$ millions)

Figure 61. France Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 62. UK Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 63. Italy Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 64. Russia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 65. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2026)

Figure 66. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2026)

Figure 67. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2021-2026)

Figure 68. Egypt Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 69. South Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 70. Israel Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 71. Turkey Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 72. GCC Countries Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth 2021-2026 (\$ millions)

Figure 73. Manufacturing Cost Structure Analysis of Neurokinin Receptor Antagonists for Vasomotor Symptoms in 2026

Figure 74. Manufacturing Process Analysis of Neurokinin Receptor Antagonists for Vasomotor Symptoms

Figure 75. Industry Chain Structure of Neurokinin Receptor Antagonists for Vasomotor Symptoms

Figure 76. Channels of Distribution

Figure 77. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Forecast by Region (2027-2032)

Figure 78. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share Forecast by Region (2027-2032)

Figure 79. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share Forecast by Type (2027-2032)

Figure 80. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue

Market Share Forecast by Type (2027-2032)

Figure 81. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales

Market Share Forecast by Application (2027-2032)

Figure 82. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue

Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G2A792748073EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2A792748073EN.html>